Ovarian Cancer

In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.

New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.

Secondary cytoreductive surgery was not associated with improvement in either OS or PFS in patients with platinum-sensitive recurrent ovarian cancer.

The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.

The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.

A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.

Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.

TPIV200 stimulates T cells to attack ovarian and triple-negative breast tumor cells that over-express the folate receptor alpha protein.

A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.

The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A study presented at the SGO Annual Meeting found that PARP-7 amplification mutations are associated with prolonged survival among patients with platinum-sensitive ovarian cancer.

A single-institution study of patients with advanced/recurrent EOCs found no overall survival differences for Caucasians and minorities who had participated in a clinical trial.

PARP inhibitors are offering new treatment options for ovarian cancer patients with known mutations, but early-stage diagnosis is still elusive.

A registry study suggests that there may be a familial association between ovarian and testicular cancers.

A large study found no association between the use of metformin or statins and the incidence of ovarian cancer in women with type 2 diabetes.

In this interview, Dr. Stephanie Blank discusses the recently released updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening, and how patients and clinicians should interpret them and take action.

Intraperitoneal (IP) chemotherapy is a reasonable treatment approach for ovarian cancer because it can directly expose the surface tissues to which the cancer has disseminated to an extremely high concentration of the chemotherapy drug.

There will be no further randomized phase III trials of cytotoxic IP chemotherapy; IP therapy in ovarian cancer will soon be an historical footnote along with other failed approaches in cancer care.

Lifastuzumab vedotin offered a modest improvement in progression-free survival over standard care in patients with platinum-resistant ovarian cancer.

A meta-analysis incorporating tens of thousands of individuals found no association between the use of antidepressants and the risk of epithelial ovarian cancer.

The novel agent prexasertib showed promising activity and was reasonably well tolerated in a phase II study of high-grade, heavily pretreated, BRCA wild-type serous ovarian carcinoma.

Use of oral contraceptives may be beneficial for chemoprevention for a range of women with different baseline cancer risks, according to the results of a new study.

Treatment with hyperthermic intraperitoneal chemotherapy along with cytoreductive surgery resulted in better survival outcomes than surgery alone in patients with stage III epithelial ovarian cancer, according to a new study.

The FDA has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer.

The addition of pazopanib to paclitaxel failed to improve outcomes over paclitaxel alone in women with persistent or recurrent epithelial ovarian cancer.

The majority of surveyed ovarian cancer patients required a 5-year survival benefit of 6% or less to justify an additional 50 miles of travel for cancer care.

Comprehensive geriatric assessments will play an increasingly important role in identifying patient frailty and personalizing geriatric oncology treatment, according to recently published reviews.

Extending the platinum-free interval following disease progression in ovarian cancer with a non-platinum agent does not improve outcomes over the standard practice of using a platinum-based chemotherapy, according to a prospective trial.

A large database study found that most patients with stage I endometrioid epithelial ovarian cancer or ovarian clear cell cancer do not have better survival outcomes when treated with adjuvant chemotherapy.

The relative importance of common chemotherapy side effects has shifted substantially over the last few decades, according to a new study. In general, psychosocial effects have become more important while physical effects seem less significant to patients than in the past.